Compare Nvidia Corp (NVDA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Novartis AG — how do they compare? Nvidia Corp trades at $223.09 (market cap $5.40T), while Novartis AG trades at $140 (market cap $262.28B). The key difference: Nvidia Corp is far larger — about 20.6× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| NVDA | NVS | |
|---|---|---|
Market Cap | $5.40T | $262.28B |
Sector | Technology | Health |
52-Week High | $235.75 | $168.62 |
52-Week Low | $165.17 | $121.80 |
Enterprise Value | $5.38T | $303.60B |
Dividend Yield | 0.45% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $225.73, down 2.01% today, with a bullish technical signal from moving averages and support near $222. The company reported robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.47. Revenue surged to $130.50B in 2025, driving a net income margin of 63.66%, while valuation ratios like P/E of 28.54 reflect high growth expectations. Analysts maintain strong buy consensus amid AI-driven demand.
Outlook remains positive due to AI leadership and accelerating revenue, but risks include competition and market volatility. The stock offers significant upside to the $344.10 consensus target, though investors should monitor execution risks and macroeconomic headwinds.
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
